Securian Asset Management Inc. Sells 3,585 Shares of IQVIA Holdings Inc. $IQV

Securian Asset Management Inc. cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 44.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,571 shares of the medical research company’s stock after selling 3,585 shares during the quarter. Securian Asset Management Inc.’s holdings in IQVIA were worth $1,030,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new position in IQVIA during the 4th quarter worth $27,000. Activest Wealth Management increased its stake in IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares during the period. Physician Wealth Advisors Inc. raised its holdings in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares in the last quarter. Finally, Westside Investment Management Inc. lifted its position in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of a number of analyst reports. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Jefferies Financial Group reduced their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. UBS Group lowered their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Finally, Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $225.69.

IQVIA Price Performance

IQV stock opened at $174.70 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market cap of $29.16 billion, a price-to-earnings ratio of 21.65, a PEG ratio of 1.67 and a beta of 1.18. The company’s fifty day simple moving average is $170.43 and its 200 day simple moving average is $200.08. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 11.52 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.